Skip to main content

Oncology · UK

Proton therapy - when it genuinely helps, and when it does not.

Pencil-beam scanning proton radiotherapy at UK and overseas centres. A consultant clinical oncologist, a plan compared honestly with IMRT and SBRT, and a full late-effects surveillance plan built in from the start.

See indicative pricing
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Indicative pricing

What private proton therapy costs from the UK.

Indicative ranges across UK proton centres and overseas facilities.

In short

£55,000–£95,000, over 6–7 weeks.

CourseIndicative range
Consultation and MDT plan comparison£450–£900
Paediatric CNS proton course (typical)£65,000–£130,000
Adult skull-base/spinal chordoma or chondrosarcoma£75,000–£130,000
Adult head and neck proton course£55,000–£95,000
Prostate proton therapy (hypofractionated)£30,000–£55,000
Re-irradiation with protons£45,000–£85,000
Ocular melanoma proton course£20,000–£35,000

Prices vary widely by centre, by disease site and by whether combined chemotherapy is needed. NHS-funded proton therapy is available for a defined list of indications; if you fit these criteria, check NHS funding before paying privately.

The problem

Proton therapy is oversold - and, for the right cases, undervalued.

Some patients pay for protons where IMRT would do the same job. Others miss out on protons where the normal-tissue advantage is genuine. It is worth separating those two before you commit.

  • Plan comparison, not a sales pitch

    Every case should include an IMRT plan comparison in the same tumour volume and immobilisation, so the difference is measured, not assumed.

  • The right modality is sometimes surgery

    For selected skull-base, spine and prostate cases, surgery or brachytherapy is a better single answer.

  • Late effects planned in from day one

    Endocrine, cognitive, cardiac, second-malignancy - surveillance is scheduled before your first fraction, not remembered at year five.

When it helps

Where protons genuinely outperform photons.

The indications where the dosimetric advantage translates into meaningful clinical benefit - plus the red flag that trumps every scheduling question.

  • Paediatric cancers

    Medulloblastoma, ependymoma, craniopharyngioma, rhabdomyosarcoma, retinoblastoma - where sparing developing brain and organs matters most.

  • Skull-base and paraspinal tumours

    Chordoma, chondrosarcoma, meningioma near optic apparatus and brainstem - protons deliver high dose while sparing critical structures.

  • Head and neck cancers

    Oropharynx, nasopharynx and salivary gland tumours where parotid, oral cavity and cochlear sparing improve quality of life.

  • Ocular melanoma

    Choroidal and iris melanoma - protons preserve the eye with a 90%+ tumour control rate in selected cases.

  • Selected adult CNS tumours

    Low-grade glioma in young adults, meningioma, craniopharyngioma - reducing radiation dose to healthy brain.

  • Re-irradiation

    When a tumour recurs in or near a previously treated volume, protons can deliver curative dose while limiting cumulative dose to critical organs.

  • Selected lymphomas

    Mediastinal Hodgkin and non-Hodgkin lymphoma in young patients - reducing heart, lung and breast dose to lower late cardiac and second-cancer risk.

  • Red flag: symptoms of spinal cord compression

    New back pain with leg weakness, bladder or bowel changes is an oncological emergency.

Delivery options

Not all protons are equal - and not every case needs them.

Modern proton delivery and the photon comparators - what each option involves and where it fits.

  • Pencil-beam scanning (PBS) protons

    The modern standard. A narrow beam paints the target voxel by voxel - best conformality, best organ sparing, and the basis for intensity-modulated proton therapy (IMPT).

  • Passive scattering

    Older delivery technique still used in a minority of centres and for uveal melanoma. Simpler, less conformal, adequate for well-defined superficial targets.

  • Intensity-modulated proton therapy (IMPT)

    PBS with multi-field optimisation - the proton analogue of IMRT. Standard for head and neck, complex CNS and re-irradiation cases.

  • Hypofractionated proton therapy

    Fewer, larger fractions - used in prostate and some liver cases. Shorter course, similar biological effect.

  • Proton stereotactic radiotherapy

    Very few fractions of very high dose for small, well-defined targets - some centres offer for liver, spine and CNS lesions.

  • Photon IMRT/VMAT (the comparator)

    For most adult cancers, photon IMRT gives equivalent disease control and is available on the NHS. Plans should always be compared.

  • Stereotactic body radiotherapy (SBRT)

    Photon SBRT is the standard for early-stage lung, oligometastatic disease and selected liver tumours. Often preferred over protons for these indications.

  • Brachytherapy

    Where relevant (prostate, cervix, some skin and head-and-neck sites), internal radiation may be a better single modality or boost than external protons.

Safety and side effects

What to expect during and after treatment - honestly.

Proton therapy is well tolerated, but every course brings site-specific reactions and long-term issues that need active management.

  • Fatigue is the near-universal effect

    Cumulative through the course, worst in the last two weeks, settling over 4–8 weeks. Plan the diary accordingly.

  • Site-specific acute reactions

    Skin dermatitis, mucositis for H&N, cystitis and proctitis for pelvis, oesophagitis for chest. Proactive symptom control from week one.

  • Late effects are the main reason people choose protons

    Lower integral dose to healthy tissue means lower long-term risk of hypothyroidism, hearing loss, xerostomia, cognitive change and second malignancy - especially in children and young adults.

  • The proton advantage is dosimetric, not always clinical

    For prostate, breast and many photon-radical cancers, the survival difference over IMRT is small or unproven. The question is whether normal-tissue sparing translates into fewer long-term problems for you.

  • Range uncertainty is real

    Proton range depends on tissue density. Weight change, air cavities, dental hardware and swallowing changes matter. Adaptive re-plans mid-course are routine.

  • Anaesthesia for young children

    Paediatric patients under 6 usually need daily general anaesthesia for immobilisation. Centres with paediatric anaesthesia are a must.

  • Fertility, thyroid and endocrine

    Where pelvis, spine or brain are treated, fertility preservation and endocrine surveillance are planned before the first fraction.

  • Re-irradiation carries specific risks

    Cumulative dose to spinal cord, brainstem and bowel is tracked carefully. Necrosis, fistula and neurological damage remain possible.

  • Red flags during treatment

    Severe throat pain preventing swallowing, breathlessness, high fever, new neurological symptoms, uncontrolled bleeding - same-day treatment-centre call or A&E.

Reading your record

Your proton therapy record in four parts. Read the last one first.

Whatever the site, the completion summary follows the same shape - target coverage, organ doses, on-treatment reactions and forward plan.

A UK consultant clinical oncologist reviewing a proton therapy treatment plan

A quiet reminder

Radiotherapy records are technical - ask your care team to explain what to watch for and when.

  1. 01Treatment summary

    Site, dose, fractions and technique

    The site treated, total dose in Gy(RBE), fraction number and size, and delivery technique (PBS/IMPT, passive scattering).

  2. 02Plan

    Target coverage and organ-at-risk doses

    How well the target volume was covered, and the doses received by nearby critical organs - with comparison to your original IMRT plan.

  3. 03On-treatment

    Acute reactions and interventions

    What reactions you had, how they were managed, whether any adaptive re-plan was needed.

  4. 04Impression

    Response, surveillance and late-effect plan

    Read this first: expected response window, imaging schedule and the late-effect surveillance plan (endocrine, cognitive, cardiac, second-malignancy).

Recognised by major UK insurers

BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

Proton therapy cover varies significantly by insurer and by indication. Bupa and AXA cover selected indications; many need pre-authorisation with dose comparison.

Frequently asked

Common questions about proton therapy.

Quick answers on cost, NHS access, side effects and how it compares with IMRT.

  • How is proton therapy different from standard (photon) radiotherapy?

    Photons deposit dose along their entire path through the body. Protons deposit most of their energy at a defined depth - the Bragg peak - and then stop. That means less dose to healthy tissue beyond the tumour, which matters most for children, tumours near critical structures, and re-irradiation.

  • Is proton therapy better than IMRT for my cancer?

    It depends on the site. For paediatric CNS tumours, skull-base chordomas, ocular melanoma and selected head-and-neck cases, protons have clear normal-tissue advantages. For prostate, breast and most lung cancers, IMRT or SBRT gives equivalent disease control. Plans should be compared before a modality is recommended.

  • Is proton therapy available on the NHS?

    Yes - the NHS runs two proton beam therapy centres (Christie in Manchester and UCLH in London) with tightly defined national criteria. Approved indications include paediatric cancers, adult skull-base and spinal chordoma and chondrosarcoma, and selected re-irradiation. Cases outside these criteria are usually funded privately or overseas.

  • What does a private proton course cost in the UK?

    Roughly £30,000–£55,000 for prostate, £55,000–£95,000 for head and neck, £65,000–£130,000 for paediatric CNS and £20,000–£35,000 for ocular melanoma.

  • How long does a course of proton therapy take?

    Prostate hypofractionated: 1–4 weeks. Ocular melanoma: 4 fractions over a week. Adult H&N and CNS: 6–8 weeks. Paediatric CNS: 5–7 weeks. Each daily session lasts 15–45 minutes including set-up; the beam is on for 1–3 minutes.

  • Will I lose my hair or feel very unwell?

    Only tissues in the beam react. Hair falls out where the beam enters or exits scalp. Nausea is uncommon unless brain, upper abdomen or wide fields are treated. Fatigue is universal, worst in the last two weeks. Site-specific reactions - mucositis, dermatitis, cystitis - are managed proactively.

  • Does proton therapy reduce the risk of second cancers?

    Yes for children and young adults, where integral body dose is much lower. The absolute reduction is small in older adults, where competing risks matter more. Second-malignancy risk is one - not the only - reason to consider protons.

  • Can I have proton therapy after previous radiotherapy?

    Sometimes. Protons are one of the few ways to deliver curative dose to a recurrence sitting in or near a previously treated volume. Every case is individually planned, and the cumulative dose to spinal cord, brainstem and bowel is tracked carefully.

Related treatments

Looking for something else?